ROS1 (L2086F)
Sign in to save this workspaceROS1 · Variant type: point · HGVS: p.L2086F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pacritinib | 99.2% | 0.8% | 88.64 |
| 2 | Gilteritinib | 96.3% | 3.7% | 88.97 |
| 3 | Fedratinib | 92.5% | 7.5% | 96.21 |
| 4 | Pralsetinib | 87.9% | 12.1% | 93.43 |
| 5 | Abemaciclib | 81.6% | 18.4% | 91.48 |
| 6 | Defactinib | 76.4% | 23.6% | 92.68 |
| 7 | Lazertinib | 76.0% | 24.0% | 97.47 |
| 8 | Tivozanib | 63.1% | 36.9% | 92.42 |
| 9 | Selpercatinib | 60.6% | 39.4% | 96.72 |
| 10 | Sunitinib | 55.8% | 44.2% | 91.73 |
| 11 | Pirtobrutinib | 55.7% | 44.3% | 99.49 |
| 12 | Gedatolisib | 54.7% | 45.3% | 99.75 |
| 13 | Neratinib | 52.6% | 47.4% | 93.18 |
| 14 | Paxalisib | 37.0% | 63.0% | 99.75 |
| 15 | Vandetanib | 35.0% | 65.0% | 95.74 |
| 16 | Alpelisib | 33.2% | 66.8% | 97.22 |
| 17 | Entrectinib | 30.9% | 69.1% | 93.69 |
| 18 | Erlotinib | 28.2% | 71.8% | 99.75 |
| 19 | Avapritinib | 27.7% | 72.3% | 97.73 |
| 20 | Repotrectinib | 27.2% | 72.8% | 84.21 |
| 21 | Tenalisib | 24.5% | 75.5% | 97.98 |
| 22 | Sorafenib | 22.8% | 77.2% | 96.72 |
| 23 | Canertinib | 20.1% | 79.9% | 96.49 |
| 24 | Pemigatinib | 18.4% | 81.6% | 98.23 |
| 25 | Remibrutinib | 15.5% | 84.5% | 99.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pacritinib | 99.2% | — | — |
| Gilteritinib | 96.3% | — | — |
| Fedratinib | 92.5% | — | — |
| Pralsetinib | 87.9% | — | — |
| Abemaciclib | 81.6% | — | — |
| Defactinib | 76.4% | — | — |
| Lazertinib | 76.0% | — | — |
| Tivozanib | 63.1% | — | — |
| Selpercatinib | 60.6% | — | — |
| Sunitinib | 55.8% | — | — |
| Pirtobrutinib | 55.7% | — | — |
| Gedatolisib | 54.7% | — | — |
| Neratinib | 52.6% | — | — |
| Paxalisib | 37.0% | — | — |
| Vandetanib | 35.0% | — | — |
| Alpelisib | 33.2% | — | — |
| Entrectinib | 30.9% | — | — |
| Erlotinib | 28.2% | — | — |
| Avapritinib | 27.7% | — | — |
| Repotrectinib | 27.2% | — | — |
| Tenalisib | 24.5% | — | — |
| Sorafenib | 22.8% | — | — |
| Canertinib | 20.1% | — | — |
| Pemigatinib | 18.4% | — | — |
| Remibrutinib | 15.5% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.4ms